The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

October 20, 2024

Study Completion Date

November 20, 2024

Conditions
Tuberculous Uveitis
Interventions
DRUG

Anti Tuberculosis Drug

ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.

DRUG

Methylprednisolone

Selected participants may be prescribed local or systemic immunosuppressants, including oral methylprednisolone, starting at a dosage of 0.8 mg/kg of body weight per day and tapered gradually (e.g., every three days or weekly) based on the severity of intraocular inflammation observed during presentation and follow-up visits.

Trial Locations (1)

10320

Cipto Mangunkusumo National Central General Hospital, Jakarta Pusat

All Listed Sponsors
lead

Fakultas Kedokteran Universitas Indonesia

OTHER

NCT05005637 - The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA | Biotech Hunter | Biotech Hunter